Monographie - Tirofiban - Stabilis 4.0

Viimane versioon :
08/05/2024

Antikoagulant

Tirofiban

Süsteravim

Stabiilsus lahustes

Stabiilsust mõjutavad tegurid

Stabiilsust mõjutavad faktorid

Sobimatus

Manustamis viis

Viited

Pdf

Kaubanduslikud nimed erinevates maades

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Aggrastat	Ameerika ühendriigid, Araabia Ühendemiraadid, Austraalia, Austria, Belgia, Holland, Iirimaa, Iraan, Itaalia, Kanada, Luksemburg, Malaisia, Norra, Poola, Portugal, Rootsi, Saksamaa, Saudi Araabia, Soome, Suurbritannia, Sveits, Taani, Türgi, Ungari, Uus-Meremaa
Agrastat	Argentiina, Brasiilia, Ecuador, Egiptus, Hispaania, Kolumbia, Maroko, Maroko, Mehhiko, Prantsusmaa, Tšiili, Venetsueela
Thrombostat	Türgi
Tirofiban	Hispaania, Saksamaa
Tiroprest	Türgi
Welban	Hispaania
Xtraban	India

Viited

Süsteravim

Viited : Tirofiban

	Tüüp	Avaldamine
1071	Ajaleht	Bergquist PA, Zimmermann J, Kenney RR, Han RYH, Hunke WA. Stability of tirofiban hydrochloride in three commonly used IV solutions and polyvinyl chloride administration sets. Am J Health-Syst Pharm 1999 ; 56: 1627-1629.
1420	Ajaleht	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1508	Ajaleht	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Labor	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1600	Ajaleht	Garabito MJ, Jimenez L, Bautista J, Santos-Rubio MD, Perez Rodrigo I. Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days. Am J Health-Syst Pharm 2001 ; 58: 1850-1851.
1603	Ajaleht	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611	Ajaleht	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1713	Ajaleht	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
2004	Ajaleht	Patel K, Hursting MJ. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1381-1384.
3823	Ajaleht	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.

Mentions Légales